MedTrace Logo

Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer

NCT03298074 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-09-29

No results posted yet for this study

Summary

It is a prospective multi-center trial, platinum-resistant ovarian cancer patients will be randomized in two groups, one group will be treated with Apatinib plus Etoposide, the other will be treated with Etoposide alone. It is aimed to see the efficacy and safety of Apatinib plus Etoposide for the platinum-resistant ovarian cancer patients

Conditions

Interventions

DRUG

Apatinib

Apatinib, 500mg,po qd for continuous administration

DRUG

Etoposide

Etoposide,100mg, PO.QD，D1-D10, Q3W

Sponsors & Collaborators

  • Yang Zhijun

    lead OTHER

Principal Investigators

  • Zhijun Yang · Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-31
Primary Completion
2018-10-31
Completion
2019-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03298074 on ClinicalTrials.gov